BioMimetic Triumphs Over Investors' Fraud Class Action

Law360, Los Angeles (January 11, 2013, 2:26 PM EST) -- A Tennessee federal judge on Thursday tossed a shareholder class action against BioMimetic Therapeutics Inc. and its two top executives, ruling that the plaintiffs had failed to prove the orthopedics company lied about the progress of approval for a bone injury treatment that decimated its stock price.

U.S. District Judge Kevin H. Sharp granted BioMimetic's bid to dismiss the suit, finding that under the pleading requirements of the Private Securities Litigation Reform Act, the investors failed to adequately support their claims that BioMimetic conducted inferior clinical...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Kuyat v. BioMimetic Therapeutics, Inc. et al


Case Number

3:11-cv-00653

Court

Tennessee Middle

Nature of Suit

Securities/Commodities

Judge

Kevin H. Sharp

Date Filed

July 6, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.